Evidence map›Paper›PMID 41230152›Full record

ArticleTranslational andrology and urology2025

Targeting FGFR1 enhances olaparib sensitivity via MAPK-mediated BRCA2 downregulation in mCRPC.

Jian Chen, Jiarun Lai, Yupeng Chen, Yusen Long, Zhaodong Han, Jiaming Su, Rui Zhou, Ziqing Zhou, Huichan He, Shaoyou Liu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jian Chen *Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID https://orcid.org/0009-0003-6024-1906
Jiarun Lai *Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yupeng Chen *Department of Urology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.ORCID https://orcid.org/0000-0002-0430-2845
Yusen LongDepartment of Urology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Zhaodong HanDepartment of Urology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Jiaming SuDepartment of Urology, Guangzhou Baiyun District Women and Children's Hospital, Guangzhou, China.
Rui ZhouGuangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Ziqing ZhouState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Huichan HeGuangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Shaoyou LiuGuangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Weide ZhongGuangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID https://orcid.org/0000-0002-0430-2845

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Olaparib has demonstrated therapeutic potential in treating metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene mutations, especially Methods: We performed integrative transcriptomic analyses of multiple mCRPC datasets to examine the correlation between Results: In this study, integrative transcriptomic analyses of multiple mCRPC datasets revealed a strong positive correlation between Conclusions: Together, these data reveal an

Indexed as

BRCA2fibroblast growth factor receptor 1 (FGFR1)metastatic castration-resistant prostate cancer (mCRPC)OlaparibPARP inhibitor resistance

Identifiers

PMID41230152
PMCPMC12603815

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.